Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

NCT06532643 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Lymphoma

Interventions

GENETIC: anti-CD20/CD30-CAR-T cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Shanghai First Song Biotechnology Co., LTD